Carlo Castellani
A5090541302- Cystic Fibrosis Research Advances
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Congenital Ear and Nasal Anomalies
- Immunodeficiency and Autoimmune Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Pediatric health and respiratory diseases
- Pancreatitis Pathology and Treatment
- Child Nutrition and Feeding Issues
- Respiratory viral infections research
- Genomics and Rare Diseases
- Esophageal and GI Pathology
- Infant Nutrition and Health
- Inhalation and Respiratory Drug Delivery
- Prenatal Screening and Diagnostics
- Pharmaceutical studies and practices
- Gastrointestinal disorders and treatments
- Antibiotics Pharmacokinetics and Efficacy
- Retinal Diseases and Treatments
- Autism Spectrum Disorder Research
- Antibiotic Resistance in Bacteria
- Child Nutrition and Water Access
- Mobile Health and mHealth Applications
- scientometrics and bibliometrics research
- Pulmonary Hypertension Research and Treatments
Istituto Giannina Gaslini
2018-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2024
Assistance Publique – Hôpitaux de Paris
2024
Université Paris Cité
2024
University of Liverpool
2024
Hôpital Cochin
2024
Institut Cochin
2024
Inserm
2009-2024
National Agency for New Technologies, Energy and Sustainable Economic Development
2023
IRCCS Humanitas Research Hospital
2016-2021
This is the second in a series of four papers updating European Cystic Fibrosis Society (ECFS) standards for care people with CF. paper focuses on establishing and maintaining health. The guidance produced using an evidence-based framework wide stakeholder engagement, including from CF community. Authors provided narrative description their topic statements, which were more directive. These statements reviewed by Delphi exercise, achieving good levels agreement group all statements....
This is the third in a series of four papers updating European Cystic Fibrosis Society (ECFS) standards for care people with CF. paper focuses on recognising and addressing CF health issues. The guidance was produced wide stakeholder engagement, including from community, using an evidence-based framework. Authors contributed sections, summary statements which were reviewed by Delphi consultation.Monitoring treating airway infection, inflammation pulmonary exacerbations remains important,...
OBJECTIVES:. To prospectively study infants with an inconclusive diagnosis of cystic fibrosis (CF) identified by newborn screening (NBS; "CF screen positive, diagnosis" [CFSPID]) for disease manifestations.METHODS:. Infants CFSPID and CF based on NBS from 8 centers were evaluated monitored. Genotype, phenotype, repeat sweat test, serum trypsinogen, microbiology data compared between subjects who did (CFSPID→CF) not (CFSPID→CFSPID) fulfill the criteria during first 3 years life.RESULTS:....
The improved survival in people with cystic fibrosis has led to an increasing number of patients reaching adulthood. This trend is likely be maintained over the next decades, suggesting a need increase centres expertise management adult fibrosis. These should capable delivering multidisciplinary care addressing complexity disease, addition psychological burden on and their families. Further issues that require attention are organ transplantation end life management. Lung disease adults...
Rationale: The advent of precision treatment for cystic fibrosis using small-molecule therapeutics has created a need to estimate potential clinical improvements attributable increases in transmembrane conductance regulator (CFTR) function. Objectives: To derive CFTR function variety genotypes and correlate with key features (sweat chloride concentration, pancreatic exocrine status, lung function) develop benchmarks assessing response modulators. Methods: assigned 226 unique was correlated...
Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to genetic variants in Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators, first therapy available, have transformed management CF. The latest standards care from European CF Society (2018) did not include guidance on as modulators were becoming established a novel therapy. We produced interim guide healthcare professionals provision for people with Here we provide evidence-based covering...